Literature DB >> 7665563

Interactions between the GroE chaperonins and rhodanese. Multiple intermediates and release and rebinding.

K E Smith1, M T Fisher.   

Abstract

Efficient renaturation of urea-denatured rhodanese using the chaperonin GroE system requires GroEL, GroES, and ATP. At high concentrations this renaturation also requires the substrate thiosulfate to have been present during GroEL-rhodanese complex formation. When thiosulfate is present the GroEL-rhodanese complex can be concentrated to greater than 1 mg/ml rhodanese with little effect on the efficiency of renaturation. However, if complex is formed in the absence of thiosulfate, renaturation of rhodanese in the presence of thiosulfate shows a critical concentration of approximately 0.4 mg/ml, above which renaturation yields drop dramatically. This critical concentration appears to be related to an aggregation event in the refolding of rhodanese. The nucleotide free or ADP-bound form of GroEL also binds to rhodanese that has been either already renatured or never denatured. The bound rhodanese has no activity but can be released from GroEL with ATP recovering 90% of control activity. The data presented herein support a release and rebinding mechanism for the GroE-assisted refolding of rhodanese. It also suggests GroEL binds several protein folding intermediates along the entire refolding pathway.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7665563     DOI: 10.1074/jbc.270.37.21517

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  15 in total

1.  Chaperonin function: folding by forced unfolding.

Authors:  M Shtilerman; G H Lorimer; S W Englander
Journal:  Science       Date:  1999-04-30       Impact factor: 47.728

2.  Nuclear magnetic resonance spectroscopy with the stringent substrate rhodanese bound to the single-ring variant SR1 of the E. coli chaperonin GroEL.

Authors:  Eda Koculi; Reto Horst; Arthur L Horwich; Kurt Wüthrich
Journal:  Protein Sci       Date:  2011-07-07       Impact factor: 6.725

3.  Folding with and without encapsulation by cis- and trans-only GroEL-GroES complexes.

Authors:  George W Farr; Wayne A Fenton; Tapan K Chaudhuri; Daniel K Clare; Helen R Saibil; Arthur L Horwich
Journal:  EMBO J       Date:  2003-07-01       Impact factor: 11.598

4.  Designing a high throughput refolding array using a combination of the GroEL chaperonin and osmolytes.

Authors:  Paul A Voziyan; Mary Johnston; Angela Chao; Greg Bomhoff; Mark T Fisher
Journal:  J Struct Funct Genomics       Date:  2005

Review 5.  GroEL-mediated protein folding: making the impossible, possible.

Authors:  Zong Lin; Hays S Rye
Journal:  Crit Rev Biochem Mol Biol       Date:  2006 Jul-Aug       Impact factor: 8.250

6.  Native-like structure of a protein-folding intermediate bound to the chaperonin GroEL.

Authors:  M S Goldberg; J Zhang; S Sondek; C R Matthews; R O Fox; A L Horwich
Journal:  Proc Natl Acad Sci U S A       Date:  1997-02-18       Impact factor: 11.205

7.  The chaperonin cycle cannot substitute for prolyl isomerase activity, but GroEL alone promotes productive folding of a cyclophilin-sensitive substrate to a cyclophilin-resistant form.

Authors:  O von Ahsen; M Tropschug; N Pfanner; J Rassow
Journal:  EMBO J       Date:  1997-08-01       Impact factor: 11.598

Review 8.  GroEL-mediated protein folding.

Authors:  W A Fenton; A L Horwich
Journal:  Protein Sci       Date:  1997-04       Impact factor: 6.725

9.  GroEL and CCT are catalytic unfoldases mediating out-of-cage polypeptide refolding without ATP.

Authors:  Smriti Priya; Sandeep Kumar Sharma; Vishal Sood; Rayees U H Mattoo; Andrija Finka; Abdussalam Azem; Paolo De Los Rios; Pierre Goloubinoff
Journal:  Proc Natl Acad Sci U S A       Date:  2013-04-12       Impact factor: 11.205

10.  Chaperonin-assisted folding of glutamine synthetase under nonpermissive conditions: off-pathway aggregation propensity does not determine the co-chaperonin requirement.

Authors:  P A Voziyan; M T Fisher
Journal:  Protein Sci       Date:  2000-12       Impact factor: 6.725

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.